At week 16, the mean percentage change from baseline in BW ranged from −5.8% to −9.7% across the CX11/VCT220 dose cohorts and was −1.6% in the placebo group. Weight reduction was significantly greater at all CX11/VCT220 doses compared to placebo. A weight reduction of at least 5% by week 16 occurred in 55% to 90% of the participants who received CX11/VCT220, as compared to 13% who received placebo.
At week 16, the mean percentage change from baseline in BW ranged from −5.8% to −9.7% across the CX11/VCT220 dose cohorts and was −1.6% in the placebo group. Weight reduction was significantly greater at all CX11/VCT220 doses compared to placebo. A weight reduction of at least 5% by week 16 occurred in 55% to 90% of the participants who received CX11/VCT220, as compared to 13% who received placebo.